MAP2K7 and lung cancer: This indicates that re-activating this kinase using adenovirus-based therapy could be used to treat this type of cancer in combination with classical drugs used in lung cancer presenting BRAF mutations, such as BRAF or MEK inhibitors, dabrafenib, or trametinib.